whether
natur
occur
manmad
biolog
threat
pose
sever
risk
increasingli
global
world
dualus
natur
biolog
research
recent
advanc
biotechnolog
synthet
biolog
gene
edit
nanotechnolog
etc
rapid
diffus
knowledg
rais
prolifer
concern
biolog
weapon
nonstat
actor
thu
urgent
need
develop
measur
intend
enhanc
diagnost
prophylact
therapeut
capabl
capac
improv
abil
societi
combat
infecti
diseas
outbreak
well
allevi
effect
bioterror
attack
present
two
exampl
biotechnolog
usag
biodef
purpos
plant
biofactori
rapid
product
improv
biopharmaceut
plant
molecular
farm
ii
plant
sequenc
immunemodul
agent
enhanc
efficaci
genet
vaccin
platform
repres
two
promis
complementari
approach
rapid
lowcost
product
countermeasur
diagnost
vaccin
candid
emerg
reemerg
bioterrorismrel
infect
keyword
infecti
diseas
sarscov
biothreat
bioweapon
genet
vaccin
molecular
farm
plant
sequenc
diagnost
infecti
diseas
repres
signific
burden
public
health
econom
stabil
societi
world
caus
approxim
million
death
develop
countri
percentag
reach
death
death
among
children
year
age
due
infecti
diseas
global
world
travel
trade
greater
interconnected
countri
infecti
diseas
outbreak
becom
inevit
remain
unpredict
face
diseas
medic
countermeasur
massiv
chao
consider
loss
live
ensu
countri
without
adequ
health
servic
vulner
impact
infecti
diseas
due
difficulti
administ
effect
medic
treatment
earli
stage
put
effect
prevent
measur
place
spectrum
biolog
risk
repres
infecti
diseas
continu
includ
event
difficult
distinguish
natur
ie
natur
occur
pandem
reemerg
infecti
diseas
unintend
consequ
research
accident
due
laboratori
accid
ignor
neglig
intent
due
sabotag
biowarfar
whatev
origin
health
threat
anywher
health
threat
everywher
thu
necessari
identifi
emerg
epidem
soon
possibl
stop
spiral
control
develop
suitabl
medic
countermeasur
novel
effect
vaccin
infecti
diseas
centuri
among
lead
caus
death
chang
fate
entir
civil
black
death
plagu
middl
age
kill
europ
popul
smallpox
twentieth
centuri
respons
million
death
decim
world
health
organ
top
caus
death
januari
http
wwwwho
child
mortal
caus
death
http
wwwwhointghochildhealthmort
causesen
http
publichealthwustleduahealththreatanywhereisahealththreateverywher
weaken
nativ
popul
america
australia
eighteenth
centuri
prior
final
erad
late
measl
centuri
caus
massiv
destruct
nativ
popul
especi
america
europ
year
declar
erad
us
spite
avail
safe
costeffect
vaccin
continu
circul
variou
part
world
caus
mani
death
global
particularli
among
young
children
spanish
influenza
epidem
kill
mani
million
peopl
worldwid
consid
devast
epidem
record
world
histori
global
disast
past
decad
least
novel
infecti
agent
affect
human
emerg
zoonot
whose
origin
shown
correl
significantli
environmentalecolog
ie
climat
chang
flood
chang
agricultur
practic
natur
disast
habitat
destruct
socioeconom
ie
increas
popul
densiti
fall
live
standard
declin
infrastructur
human
travel
conflict
social
instabl
kill
wild
anim
food
factor
factor
togeth
natur
evolut
pathogen
constantli
lead
facilit
infect
human
chang
natur
biolog
risk
increas
global
impact
particular
newli
emerg
infect
refer
diseas
discov
human
host
first
time
ie
sever
acut
respiratori
syndrom
sarscoronaviru
sarscov
reemerg
infecti
diseas
defin
infecti
diseas
reappear
usual
pathogen
form
rapidli
increas
incid
new
geograph
locat
appar
control
erad
ie
filovirus
like
ebola
marburg
field
emerg
diseas
explor
strengthen
creation
dedic
emerg
diseas
unit
programm
centr
diseas
control
prevent
cdc
european
centr
diseas
prevent
control
ecdc
institut
monitor
current
infecti
diseas
outbreak
assess
risk
public
health
provid
technic
support
useu
levelrespons
threat
emerg
pathogen
result
deliber
human
action
employ
biolog
weapon
bioweapon
biolog
warfar
bw
destruct
among
socal
cbrn
weapon
biolog
weapon
includ
measl
http
emerg
diseas
http
wwwwhointtopicsemergingdiseasesen
global
infecti
diseas
surveil
http
wwwwhointmediacentrefactsheet
http
ecdceuropaeuenaboutuswhowearediseaseprogrammesemergingandvectorbornediseasesprogramm
cbrn
chemic
biolog
radiolog
nuclear
deadli
pathogen
bacteria
virus
toxin
deliber
releas
order
caus
harm
peopl
anim
plant
agroterror
addit
potenti
catastroph
immedi
impact
agent
could
also
trigger
longterm
disast
caus
region
instabl
challeng
intern
secur
biolog
agent
easili
grown
dissemin
inhal
ingest
skin
absorpt
might
affect
larg
number
peopl
highli
contagi
sarscov
other
might
less
contagi
deadli
affect
ebola
sinc
bioweapon
use
could
resembl
natur
pandem
would
difficult
differenti
natur
occur
infect
result
malici
use
spite
difficulti
evalu
bw
true
frequenc
use
impact
past
due
lack
data
manipulationsecret
polit
author
etc
histor
analysi
shown
biolog
agent
use
sever
occas
ancient
time
twentyfirst
centuri
caus
panic
terror
among
civil
popul
comprehens
histori
biolog
warfar
see
barra
greub
biolog
weapon
convent
bwc
sign
enter
forc
bestow
prohibit
weaponis
biolog
pathogen
agent
particular
bwc
prohibit
possess
biolog
agent
except
prophylact
protect
peac
purpos
ii
develop
technolog
intend
dispers
biolog
agent
offens
militari
purpos
iii
destruct
exist
stock
despit
destruct
potenti
bioweapon
rel
eas
malici
actor
could
obtain
mani
materi
knowhow
requir
build
rel
case
bioterror
sabotag
record
twentieth
twentyfirst
centuri
period
global
total
cbrn
attack
use
bw
potenti
disincent
acquisit
use
bw
might
repres
fact
biolog
agent
indiscrimin
easili
contain
releas
hand
specialist
rais
question
whether
bioterror
myth
realiti
use
chemic
biolog
radiolog
nuclear
weapon
nonstat
actor
emerg
trend
risk
factor
lloyd
emerg
risk
report
chatman
hous
royal
institut
intern
affair
p
http
wwwlloydscomnewsandinsightriskinsightlibrarysocietyandsecuritycbrn
bwc
current
statesparti
six
signatori
central
african
republ
egypt
haiti
somalia
syria
tanzania
twelv
state
neither
sign
ratifi
bwc
chad
comoro
djibouti
eritrea
israel
kiribati
micronesia
namibia
niue
samoa
south
sudan
tuvalu
analog
chemic
weapon
convent
cwc
sign
enter
forc
incorpor
gener
claus
prohibit
weaponis
chemic
dedic
un
negoti
treati
prohibit
nuclear
weapon
tpnw
sign
countri
recent
juli
http
http
wwwarmscontrolorgfactsheetsbwcsig
nation
consortium
studi
terror
respons
terror
start
global
terror
databas
onlin
avail
http
wwwstartumdedugtd
other
consid
bw
common
aspect
human
behaviour
repertoir
knowledg
diffus
rapidli
differ
part
world
globalis
inform
commun
technolog
grow
concern
emerg
biolog
agent
could
easili
use
weapon
nonstat
actor
terrorist
organis
saboteur
lone
actor
futur
moreov
certain
emerg
technolog
scientif
advanc
biotechnolog
ie
nanotechnolog
synthet
biolog
gene
edit
alter
risk
landscap
bioweapon
use
varieti
way
dual
use
concept
malici
use
synthet
edit
pathogen
could
possibl
enabl
hostil
actor
develop
weapon
cheaper
power
easier
use
ie
deadli
virus
polio
ebola
synthes
use
public
databas
avail
technolog
highli
unlik
societi
could
ever
complet
elimin
vulner
biolog
agent
doubt
topic
biolog
warfar
pose
difficult
problem
open
novel
challeng
ethic
domain
sinc
biolog
agent
might
lethal
chemic
weapon
difficult
detect
nuclear
weapon
less
expens
produc
use
common
technolog
avail
biolog
laboratori
measur
intend
enhanc
mitig
diagnost
surveil
etc
adapt
new
therapeut
vaccin
etc
capabl
capac
alongsid
train
educ
improv
abil
societi
combat
regular
infecti
diseas
outbreak
well
counteract
effect
bioterrorist
attack
enhanc
societi
resili
novel
technolog
nanotechnolog
new
detect
technolog
next
gener
sequenc
could
use
cleanup
detect
preserv
health
wellb
first
respond
assist
local
law
enforc
identifi
natur
outbreakattack
kind
biolog
agent
involv
make
respond
easier
reduc
destruct
disrupt
capac
biolog
threat
hand
antimicrobi
vaccin
offer
possibl
mean
protect
toward
sudden
emerg
infecti
diseas
outbreak
natur
intent
import
reli
strateg
reserv
therapeuticsvaccin
known
biothreat
agent
well
toolsplatform
rapid
product
effect
countermeasur
novel
pathogen
gener
pharmaceut
industri
much
involv
vaccin
rare
invest
research
develop
diseas
limit
market
incent
ebola
outbreak
began
vaccin
candid
unavail
stall
pipelin
repeat
outbreak
recent
ebola
zika
forg
global
consensu
current
model
develop
vaccin
sporad
epidem
work
new
system
urgent
need
also
light
pathogen
terrifi
expens
sar
epidem
cost
billion
month
thu
novel
global
approach
need
drive
product
innov
prevent
contain
futur
infecti
diseas
epidem
year
ago
defens
advanc
research
project
agenc
darpa
us
start
support
new
technolog
radic
acceler
manufactur
protein
vaccin
proteinbas
therapeut
realiz
lowcost
plantderiv
vaccin
better
tool
control
mani
infecti
diseas
human
darpa
financ
project
develop
cgmp
facil
plantmad
vaccin
darpa
fund
inovio
pharmaceut
inc
million
develop
multipl
treatment
prevent
approach
ebola
dnabas
vaccin
ebola
therapeut
dnabas
monoclon
antibodi
product
convent
monoclon
antibodi
treat
ebola
recent
biolog
technolog
offic
bto
darpa
sponsor
pandem
prevent
platform
program
whose
goal
achiev
integr
capabl
deliv
pandem
prevent
countermeasur
patient
within
day
outbreak
chang
outbreak
respons
enabl
rapid
discoveri
character
product
test
efficaci
medic
countermeasur
ie
gener
viru
stock
includ
viral
unknown
rapid
evolut
antibodi
candid
geneencod
antibodi
deliveri
method
anoth
initi
repres
global
health
secur
agenda
ghsa
launch
februari
grow
partnership
nation
intern
organ
nongovernment
stakehold
pursu
multilater
multisector
approach
strengthen
global
capac
nation
capac
prevent
detect
respond
infecti
diseas
threat
whether
natur
occur
deliber
accident
idea
capac
establish
would
mitig
devast
effect
threat
pose
highli
pathogen
infecti
diseas
bioterror
event
rapidli
detect
transpar
report
outbreak
occur
employ
interconnect
global
network
respond
effect
limit
spread
infecti
diseas
outbreak
human
anim
mitig
human
suffer
loss
human
life
reduc
econom
impact
besid
socal
one
health
initi
strategi
control
diseas
across
speci
recent
januari
coalit
epidem
prepared
innov
cepi
launch
world
econom
forum
partnership
public
privat
philanthrop
civil
organ
acceler
safe
afford
vaccin
develop
emerg
infecti
diseas
particularli
diseas
lack
market
incent
readi
pandem
defenc
peacetim
base
memorandum
understand
world
health
organ
establish
partnership
bill
melinda
gate
foundat
govern
like
india
germani
japan
norway
industri
partner
privat
funder
ie
wellcom
trust
academ
institut
civil
societi
organis
among
other
accord
r
blueprint
action
prevent
epidem
indic
prioriti
pathogen
develop
medic
countermeasur
urgent
need
base
specif
criteria
risk
outbreak
occur
transmiss
pathogen
burden
diseas
feasibl
vaccin
develop
current
pipelin
candid
first
step
three
diseas
select
lassa
fever
nipah
viru
middl
east
respiratori
syndrom
coronaviru
merscov
move
new
vaccin
preclin
proof
principl
studi
human
howev
sinc
alway
unknown
select
pathogen
possibl
predict
cepi
aim
also
support
develop
rapid
adapt
vaccin
technolog
platform
antigen
new
pathogen
substitut
ad
exist
vaccin
tradit
vaccin
infecti
diseas
fail
satisfi
global
demand
limit
scalabl
product
system
long
product
timelin
similar
issu
applic
antiinfect
agent
especi
problem
emerg
pathogen
carri
inher
risk
pandem
spread
popul
consider
number
differ
platform
technolog
develop
among
plantderiv
vaccin
plasmidbas
dna
vaccin
encourag
tool
plant
emerg
promis
platform
product
subunit
vaccin
monoclon
antibodi
recombin
therapeut
protein
plant
molecular
farm
due
time
cost
effici
scalabl
lack
harbour
mammalian
pathogen
abil
perform
eukaryot
posttransl
protein
modif
recent
appar
success
fight
ebola
viru
plantmad
human
antibodi
put
spotlight
enorm
potenti
platform
applic
human
health
far
sever
candid
countermeasur
emerg
reemerg
bioterrorismrel
infect
produc
plant
review
rybicki
streatfield
et
al
modular
molecular
engin
provid
fast
scalabl
system
use
respons
new
outbreak
highli
infecti
diseas
pandem
potenti
influenza
malaria
sar
addit
genet
vaccin
repres
anoth
advantag
platform
rapid
develop
novel
vaccin
face
deliber
natur
occur
outbreak
due
eas
prepar
gener
stabil
room
temperatur
case
plant
might
exploit
sourc
immunemodul
sequenc
abl
increas
visibl
immun
system
weak
antigen
construct
power
genet
vaccin
herbal
medicin
form
basi
health
care
throughout
worldwid
sinc
dawn
civil
extens
utilis
ancient
civilis
thousand
plant
speci
contribut
develop
import
therapeut
drug
use
modern
medicin
almost
synthet
medicin
deriv
phytochem
almost
pharmaceut
approv
us
food
drug
administr
fda
botan
origin
digoxin
morphin
salbutamol
aspirin
repres
success
exampl
use
plant
bioreactor
plant
molecular
farm
pmf
rel
new
bioscienc
far
varieti
subunit
vaccin
monoclon
antibodi
therapeut
protein
produc
plant
green
system
includ
candid
countermeasur
emerg
reemerg
bioterrorismrel
infect
plant
repres
ideal
platform
recombin
protein
product
sever
reason
lower
manufactur
cost
wide
assum
intrins
advantag
plantbas
product
platform
biolog
product
plant
requir
capitalprohibit
facil
bioreactor
expens
cultur
media
easili
scale
rel
inexpens
greenhous
simpl
miner
solut
plant
compet
express
system
reduc
risk
contamin
humananim
pathogen
abil
perform
eukaryot
posttransl
protein
modif
glycosyl
differ
nglycan
oglycan
structur
plant
mammal
nevertheless
possibl
control
glycosyl
pattern
glycoengin
plant
glycobiotechnolog
provid
method
produc
protein
uniqu
uniform
mammalian
posttransl
modif
result
biolog
increas
efficaci
respect
mammalian
cellproduc
counterpart
biobett
offici
enter
plant
scienc
field
year
specif
session
congress
plant
molecular
biolog
quebec
canada
recombin
protein
select
express
particular
plant
cell
compart
chloroplast
apoplast
etc
organ
seed
root
tuber
etc
stabl
interfer
veget
growth
plant
cellstissu
organ
lyophil
store
ambient
temperatur
mani
year
maintain
activ
express
protein
drug
promis
approach
use
edibl
plant
tissuesorgan
express
biopharmaceut
direct
oral
deliveri
need
exhaust
purif
thu
elimin
expens
downstream
purif
cold
storag
transport
cost
could
particularli
use
veterinari
vaccin
major
zoonot
diseas
furthermor
plantbas
express
platform
offer
safe
inexpens
potenti
limitless
way
produc
therapeut
quick
flexibl
manner
time
express
level
might
repres
limit
transgen
technolog
overcom
transient
express
mediat
plant
virus
agroinfiltr
recent
novel
transient
express
vector
develop
allow
product
vaccin
therapeut
unpreced
speed
recent
appar
success
fight
ebola
outbreak
plantmad
drug
cocktail
three
human
monoclon
antibodi
brought
renew
attent
field
plantmad
biolog
human
health
whose
potenti
capac
produc
rapid
respons
vaccin
alreadi
demonstr
commit
sever
us
compani
product
million
dose
influenza
vaccin
month
use
technolog
anoth
field
plant
could
repres
ideal
product
system
antigen
prepar
develop
diagnost
test
particularli
use
pathogen
grown
lab
highli
virul
need
methodolog
safe
fast
afford
product
necessari
reli
high
qualiti
reagent
earli
effort
field
pmf
focus
express
intracellular
antibodi
intrabodi
obtain
plant
resist
viral
infect
plantibodymedi
resist
particular
dealt
cucumb
mosaic
viru
cmv
tomato
spot
wilt
viru
tswv
famili
bunyavirida
sinc
introduct
vector
frankliniella
occidentali
europ
becom
one
limit
factor
one
seriou
threat
veget
crop
mediterranean
basin
later
focus
use
plantbas
platform
product
recombin
protein
develop
novel
protectiontherapi
tool
diagnost
quickli
manufactur
low
cost
minim
risk
infect
agent
like
human
papillomaviru
hpv
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
sever
acut
respiratori
syndrom
sar
emerg
spread
countri
contin
lead
infect
patient
global
fatal
rate
aetiolog
agent
syndrom
rapidli
identifi
coronaviru
sarscov
cross
speci
barrier
infect
human
show
high
morbid
mortal
rate
end
sar
outbreak
declar
juli
howev
sever
local
outbreak
subsequ
report
china
consequ
accident
laboratori
contamin
infect
contact
anim
infect
sarscov
strain
significantli
differ
predomin
outbreak
high
transmiss
high
lethal
signific
impact
public
health
system
sarscov
defin
class
c
biolog
weapon
center
diseas
control
prevent
current
approv
antivir
treatment
sarscov
sinc
sar
epidem
may
recur
time
futur
includ
r
blueprint
action
prevent
epidem
list
multipl
therapeut
approach
sarscov
merscov
current
develop
recent
exampl
effort
repres
nucleotid
prodrug
current
clinic
develop
treatment
ebola
viru
diseas
show
inhibit
sarscov
merscov
replic
multipl
vitro
system
mous
model
sarscov
pathogenesi
anoth
import
key
prevent
control
futur
outbreak
sar
develop
novel
rapid
specif
diagnost
method
addit
alreadi
avail
suspect
patient
correctli
triag
isol
sarscov
four
major
viral
structur
compon
spike
envelop
e
membran
nucleocapsid
n
protein
nonstructur
protein
structur
n
protein
abund
protein
respect
viru
core
viral
envelop
n
protein
express
earli
stage
infect
trigger
earli
power
antibodi
respons
host
thu
consid
best
diagnost
target
furthermor
sinc
n
protein
abl
induc
longterm
cellmedi
immun
respons
anim
model
repres
potenti
vaccin
candid
product
recombin
n
protein
achiev
varieti
heterolog
express
system
eukaryot
platform
insect
cell
yeast
allow
effici
specif
diagnost
test
membran
glycoprotein
function
involv
assembl
bud
virion
cell
protein
contain
cell
epitop
avail
recombin
protein
combin
recombin
viral
protein
might
overcom
concern
sensit
specif
n
proteinbas
assay
thu
provid
high
qualiti
reagent
detect
antibodi
infect
human
host
recent
demonstr
plant
transient
express
system
use
produc
sarscov
n
antigen
n
fulllength
gene
deriv
frankfurt
isol
human
sarscov
insert
differ
plant
express
vector
n
protein
express
nicotiana
benthamiana
plant
use
potato
viru
x
pvx
mediat
infect
protein
obtain
system
leav
infect
plant
differ
n
protein
produc
bacteria
plantproduc
n
protein
nt
display
proteolysi
demonstr
suitabl
plant
platform
product
recombin
sarscov
antigen
fig
addit
demonstr
crude
extract
contain
n
protein
purifi
plantproduc
n
protein
specif
recogn
immunoblot
sera
deriv
chines
sar
convalesc
patient
outbreak
patient
affect
unrel
respiratori
diseas
studi
repres
first
demonstr
plantderiv
n
protein
abl
reveal
direct
serolog
human
nspecif
antibodi
present
sera
sar
patient
thu
pro
vide
adequ
instrument
develop
rapid
lowcost
immunebas
diagnost
assay
use
altern
associ
molecular
diagnosi
protein
demonstr
wild
type
protein
toxic
express
bacteria
mutat
form
obtain
system
accumul
inclus
bodi
contrari
demonstr
plant
allow
express
fulllength
origin
protein
particular
obtain
solubl
protein
n
benthamiana
plant
use
agrobacterium
tumefaciensmedi
infect
reduc
electrophoret
mobil
observ
plantderiv
protein
compar
produc
bacteria
suggest
presenc
glycosyl
nativ
protein
nglycosyl
fourth
residu
provid
eukaryot
system
result
provid
proof
principl
use
plant
robust
rapid
flexibl
product
system
protein
reagent
suitabl
face
potenti
recur
sarscov
outbreak
dna
vaccin
repres
new
mileston
technolog
effort
infecti
diseas
offer
mani
advantag
vaccin
approach
due
simplic
eas
manufactur
safeti
dna
vaccin
current
use
veterinari
medicin
one
main
problem
solv
human
dna
vaccin
prevent
therapeut
poor
abil
induc
adequ
immun
respons
product
antibodi
andor
cellmedi
respons
sever
strategi
develop
improv
dna
vaccin
efficaci
ie
codon
optim
transfect
reagent
root
administr
adjuv
combin
heterolog
boost
increas
understand
molecular
event
drive
innat
adapt
immun
respons
assist
develop
molecular
adjuv
dna
vaccin
use
adjuv
compris
plasmidencod
signal
molecul
includ
cytokin
chemokin
immun
costimulatori
molecul
tolllik
receptor
agonist
inhibitor
immun
suppress
pathway
anoth
possibl
dna
immun
combat
threat
emerg
infecti
diseas
offer
uniqu
power
approach
product
highqual
antibodi
polyclon
monoclon
recombin
antibodi
phage
display
librari
variou
pathogen
compar
tradit
proteinbas
immun
approach
dna
immun
effici
test
novel
immunogen
design
requir
product
purif
protein
pathogen
use
recombin
protein
technolog
effect
gener
antibodi
conformationsensit
target
recent
clinic
data
shown
novel
dna
vaccin
design
abl
induc
highlevel
antigenspecif
antibodi
respons
search
innov
immunestimulatori
sequenc
clinic
use
constraint
ie
possibl
autoimmun
respons
induc
protein
human
origin
still
open
field
follow
exampl
success
use
sequenc
plant
origin
immuneenhanc
purpos
reinvent
vaccin
design
report
sever
year
ago
demonstr
therapeut
anticanc
dna
vaccin
potenti
use
plant
immunemodul
sequenc
drive
idea
plant
protein
involv
plant
defenc
respons
due
similar
mammalian
plant
immun
mechan
might
effect
tumour
human
immun
modul
innat
immun
function
turn
possibl
true
induc
tumourspecif
antigen
tsa
link
adapt
cellmedi
immun
crucial
cancer
resolut
recent
develop
genet
vaccin
plant
protein
signal
sequenc
ss
fuse
ntermin
portion
crucial
viral
antigen
deriv
human
papillomaviru
type
hpv
syntheticfus
gene
deriv
protein
mammalian
cell
transfect
studi
transient
express
intracellular
fate
protein
encod
novel
dna
construct
case
construct
protein
found
cultur
medium
transfect
cell
wherea
without
sswa
present
cell
lysat
demonstr
abil
plant
signal
sequenc
modul
sort
heterolog
protein
mammalian
cell
plant
sswa
found
modifi
process
also
construct
ie
gene
fuse
coat
protein
potato
viru
x
even
though
secret
observ
cultur
medium
protein
detect
mostli
cytoplasm
transfect
cell
immunolog
effect
ssprovid
dna
vaccin
studi
anim
model
hpv
mice
primeboost
schedul
impli
use
electropor
ep
intramuscular
immun
demonstr
plant
signal
sequenc
enhanc
humor
respons
dnabas
vaccin
electropor
ep
inde
appear
promis
approach
improv
immunogen
dna
vaccin
abil
increas
cellular
permeabl
result
high
level
protein
express
improv
immun
respons
recent
clinic
trial
shown
vaccin
schedul
compris
prime
dna
plasmid
time
zero
boost
dna
interv
intraderm
id
ep
immun
result
induct
strong
humor
immun
respons
confirm
id
ep
effici
intramuscular
im
vaccin
particular
plasmid
abl
produc
highest
titer
igg
ep
immun
protocol
determin
also
longstand
humor
immun
respons
l
persist
least
month
util
mous
model
preliminari
experi
seem
indic
neutral
natur
antibodi
best
knowledg
first
demonstr
signal
sequenc
plant
protein
may
exert
biolog
activ
mammalian
cell
enhanc
immunogen
antigen
interest
approach
might
work
also
antigen
even
rel
larg
glycoprotein
differ
pathogen
open
new
perspect
design
dna
vaccin
especi
counteract
infect
fast
effect
humor
respons
need
genet
vaccin
easili
produc
industri
scale
accord
gmp
provid
effect
safe
vaccin
involv
product
chemocytokin
might
induc
secondari
respons
anim
antigen
could
caus
cross
autoimmun
respons
order
avoid
devast
loss
life
possibl
viral
outbreak
next
ebola
zika
avian
flu
mer
biolog
warfar
bw
attack
whose
epidemiolog
associ
sudden
unforeseen
contagi
burst
necessari
reli
small
stockpil
readi
next
outbreak
begin
time
fundament
invest
technic
platform
abl
cut
time
tailor
eventu
vaccin
candid
effect
epidem
word
outbreak
happen
vaccin
readi
weeksmonth
fieldtest
massmanufactur
two
platform
introduc
plant
bioreactor
product
biopharmaceut
plant
molecular
farm
improv
genet
vaccin
endow
plant
sequenc
immunemodul
activ
repres
two
promis
complementari
approach
rapid
afford
product
countermeasur
diagnost
vaccin
candid
emerg
reemerg
bioterrorismrel
infect
